Kilroy Realty Corporation released its fourth‑quarter and full‑year 2025 financial results on February 9, 2026. Revenue rose to $272.2 million, beating the consensus estimate of $270.63 million, while Funds From Operations (FFO) per diluted share fell to $0.97, a $0.01 miss against the $0.98 estimate. The company reaffirmed its 2026 FFO guidance of $3.25 to $3.45 per share, signaling confidence in continued leasing momentum and operational improvements.
The quarter’s revenue decline of 4.8% from the $286.4 million reported in Q4 2024 reflects a 5.5% drop in GAAP and cash rents on second‑generation leases, a headwind that offset gains in life‑science leasing. Net income fell sharply to $12.4 million from $59.5 million in Q4 2024, while FFO per share dropped from $1.20 to $0.97. Over the full year, revenue slipped 1.9% to $1,112.7 million, and FFO per share fell from $4.59 to $4.20, underscoring the impact of a softer office market and higher operating costs.
The FFO miss is largely attributable to the revenue decline and a modest increase in operating expenses, including higher property‑management fees and capital‑expenditure commitments for life‑science redevelopment projects. While the company’s leasing pipeline remains robust—827,000 sq ft leased in Q4 and 2.05 million sq ft for the year—the lower occupancy rate of 81.6% and the decline in cash rents have tightened profitability. The $0.01 miss, though small, signals that the company’s cost‑control gains are not fully offsetting the revenue drag.
Revenue beat the estimate because strong demand in the life‑science segment and premium office leasing in high‑quality submarkets pushed top‑line growth. The company’s focus on high‑quality, amenitized office and life‑science properties has attracted tenants willing to pay higher rents, partially offsetting the decline in legacy office rents. However, the overall revenue decline indicates that the broader office market remains a challenge, and the company is actively reallocating assets toward life‑science and high‑growth submarkets to mitigate this risk.
Guidance for 2026 remains unchanged, with FFO per share projected at $3.25 to $3.45. Management highlighted continued momentum in leasing and capital recycling, noting that the company has sold several legacy office assets and reinvested proceeds into life‑science developments. The guidance reflects confidence that the company’s strategic shift will generate higher operating leverage and stronger cash flows in the coming years, even as it navigates a challenging office backdrop.
CEO Angela Aman emphasized that the quarter “capped an exceptional year of execution” and that the company is “well positioned for continued growth and evolution.” Investors reacted cautiously, citing the FFO miss and year‑over‑year declines in revenue and FFO as key headwinds, while the company’s focus on life‑science leasing and capital recycling was viewed as a positive tailwind for long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.